New drug could be first to stop deadly fatty liver disease
Researchers at University of California San Diego School of Medicine have identified a new investigational drug that shows promise in treating metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease linked to obesity and type 2 diabetes that can lead to cirrhosis, liver failure, and even liver cancer. The study, published in the Read more about New drug could be first to stop deadly fatty liver disease[…]